S&P DJI Announces March 2021 Quarterly Rebalance
Filed with ASX · · 9 pages · English
Earlier from Cyclopharm
- Confirmation of Technegas USFDA Timetable
- Cyclopharm Receives $3.1M R&D Tax Incentive for FY2020
- Cyclopharm Successfully Completes A$30 Million Placement
- SNMMI Requests USFDA to Expedite Approval For Technegas
- USFDA Approval Progress for Technegas and Business Update
Later from Cyclopharm
- Chairmans Address to Shareholders
- CYC 2021 AGM Presentation
- Managing Directors Address to Shareholders
- CYC First Half Trading Update
- Half Year 2021 Financial Results
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm